Member Log In


News from our community

  • 4 Sep 2020 5:00 AM | Deleted user

    Semester long internship to focus on nonprofit business operations and marketing

    BIO Alabama welcomes three students into it’s fall internship program, a program for college students who are intrinsically curious about Alabama’s bioscience industry and are motivated to promote the intellectual and innovative capital that make our state a premier place to invest, start, and grow in bioscience.

    Meryle Brown is a senior at Alabama Agricultural & Mechanical University (AAMU) majoring in business administration with a concentration in MIS.  

    “BIO Alabama is a mission driven organization committed to promoting our State’s bioscience community. While the bioscience industry is new to me, bioscience companies need business professionals, too.,” Brown said. “Interning with BIO Alabama will allow me to explore the industry and evaluate possible career tracks related to my undergraduate focus.”


    Savannah Grace Knight is a biology student at the University of Alabama in Huntsville

    “I was always a very curious kid and as the daughter of a science teacher I began dissecting frogs and using microscopes in first grade. Once I settled on a major and career path, I found myself growing more passionate about topics such as scientific literacy and women in STEM,” Knight said. “I became involved with the American Association of University Women and participated in events such as Tech Trek and helped start UAH's own branch of AAUW. An internship with BIO Alabama falls right in line with my personal passion and my desire to work in a STEM career,” Knight adds.



    Ariel Wright is a junior at Alabama Agricultural & Mechanical University (AAMU) majoring in marketing. She is also a Forbes 30 Under 30 Scholar.  

    “This year has been a year of change, a time for new experiences to learn and grow. Furthering my education endeavors with an internship with BIO Alabama will not only allow me to advance my marketing skills but will also teach me more about the impact bioscience has in Alabama,” Wright said. “I hope to continue to build my professional network and grow my knowledge of marketing strategy and tactics.”

    Brown, Knight, and Wright will spend their fall semester supporting BIO Alabama’s virtual annual conference by assisting in the implementation of conference operations and marketing plans. Once the conference concludes in October, each intern will transition to projects associated with BIO Alabama’s strategic economic development roadmap which is focused on three areas 1) business attraction and retention; 2) workforce development; and 3) startup and tech transfer.

    “We began our internship program this past summer with four students and we’re delighted to have three students on board for our fall internship program. Workforce development is a key focus area for BIO Alabama and internships are an incredible way to engage our next generation of professionals,” said Sonia Robinson, executive director of BIO Alabama. “We aim to provide students with real projects that they can own, shape, and manage from start to completion. This not only gives them tangible deliverables for their specific internship criteria, but they become immersed in the Alabama bioscience community. Our hope is that our student interns find our community  inviting and promising as they navigate options for their first career right out of college,” Robinson adds. “Our University partners graduate top talent and we want them to stay, work, and play in Alabama.”

    BIO Alabama provides remote internship opportunities throughout the year. Interested students may email their cover letter and resume to sonia@bioalabama.com.  In addition to BIO Alabama, a number of bioscience companies across the state welcome interns. Interested students may contact BIO Alabama for more information. Bioscience companies who have available internships are encouraged to send internship opportunities to BIO Alabama for assistance in promoting those opportunities to partner colleges and universities.  

    Interns support the executive director in further connecting our bioscience ecosystem. Internships with BIO Alabama are for college credit and follow the college or university's internship guidelines including minimum hour requirements and deliverables.

  • 3 Sep 2020 1:09 PM | Deleted user

    Washington, D.C. (September 3, 2020) — As America’s researchers race to develop the scientific solutions needed to eradicate Covid-19, leaders within the Biotechnology Innovation Organization (BIO) released an open letter to their biopharmaceutical colleagues that articulates key principles to ensure the “integrity, transparency, and objective assessment” of Covid-19 clinical data and secure public trust in new medical products developed in response to the pandemic. As these long-standing leaders within the biotech industry note:

    “The biopharmaceutical industry is at the center of the world’s fight against Covid-19, leading the effort to develop new vaccines, therapeutic medicines and diagnostics. Over time, we expect these efforts to be successful, resulting in a range of new healthcare products for the benefit of the entire world. …

    “As data begin to emerge from clinical trials of an array of vaccines and therapeutics, we believe that it is important for us in the biopharmaceutical industry to articulate the principles we see as essential for assessing these data and determining their potential value. We believe that public health, and the public’s trust in new medical products, are dependent upon the integrity, transparency and objective assessment of new data as they emerge.”

    The open letter articulates the following core principles:

    • Clinical trials should be conducted according to best practices to assure credibility of the data, as well as the ethical participation of a diverse population of subjects.
    • Companies should disclose important clinical data via well-respected scientific meetings or rigorous, independent peer review journals, and companies that need to release data in advance of publication should do so thoughtfully and not through press release alone.
    • The FDA should maintain its historic independence as the gold-standard international regulatory body, free from external influence.
    • The appropriate use and distribution of any new products should be data-driven, including through data collected during longer-term studies.
    • Political considerations should be put aside by leaders in both parties and they should “reassure the public that politics will not influence the development and approval of new medicines.” 

    In conclusion, the letter urges everyone “involved in the development, review, approval, and distribution of COVID-19 therapeutics and vaccines to commit themselves to these principles." To read the entire letter, click here. The letter was signed by the following individuals who are leaders within both BIO and the biopharmaceutical industry writ large:

    Jeremy M. Levin, DPhil, MB BChir
    Chairman of the Board and CEO Ovid Therapeutics
    Chair, Biotechnology Innovation Organization (BIO)

    Paul J. Hastings
    President and CEO Nkarta Therapeutics, Inc.
    Vice Chair, Biotechnology Innovation Organization (BIO)

    Ted W. Love, MD
    President and CEO Global Blood Therapeutics
    Chair, Emerging Companies Section Governing Board
    Biotechnology Innovation Organization (BIO)

    Michelle McMurry-Heath, MD, PhD
    President and CEO
    Biotechnology Innovation Organization (BIO)

    Ron Cohen, MD
    President and CEO Acorda Therapeutics, Inc.
    Past Chair, Biotechnology Innovation Organization (BIO)

    Rachel K. King
    Founder and CEO GlycoMimetics, Inc.
    Past Chair, Biotechnology Innovation Organization (BIO)

    John Maraganore, PhD
    CEO Alnylam Pharmaceuticals, Inc.
    Past Chair, Biotechnology Innovation Organization (BIO)

    Richard Pops
    Chairman & CEO Alkermes, Inc.
    Past Chair, Biotechnology Innovation Organization (BIO)

  • 1 Sep 2020 6:36 AM | Deleted user

    BIO Alabama, the leading advocate for Alabama’s bioeconomy, today announced the keynote speakers and lineup for the organization’s virtual annual conference scheduled this fall, October 5-9, 2020. While the look and feel of large gatherings is much different this year, one thing is certain - BIO Alabama is preparing a conference designed to INSPIRE, EDUCATE, and CONNECT our State’s researchers, scientists, startups, manufacturers, small, medium and large bioscience companies, investors, students, and economic developers.  

    During this conference, BIO Alabama will amplify the innovative work of its members, partners, and the broader Alabama bioscience community. Throughout the conference, attendees will hear from industry thought leaders who will discuss various topics including, but not limited to, responses to COVID-19, diversity, equity, and inclusion, biopharmaceutical manufacturing, precision and genomics medicine, bioagriculture, nanotechnology, funding, and economic development. 

    The current roster of speakers participating in BIO Alabama’s virtual annual conference includes the following keynote speakers:

    Dr. Michelle McMurry-Heath: A medical doctor and molecular immunologist by training, Dr. McMurry-Heath becomes just the third chief executive to steward the world’s largest biotechnology advocacy group, BIO - Biotechnology Innovation Organization, since its founding in 1993. The common thread in McMurry-Heath’s work across academia, government and industry has been her focus on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge innovation. Driven by her own past family experiences navigating clinical trials and funding uncertainties within the rare disease community, McMurry-Heath calls “the distribution of scientific progress the social justice issue of our age.” She is scheduled to deliver the opening keynote address on Monday, October 5 at 12:30 p.m. CST.


    Bob Hess: As Vice Chairman of Global Corporate Services at Newmark Knight Frank, Hess is a preeminent, sought-after service provider and respected leader in corporate location strategy and site selection. He has demonstrable and referenceable life sciences and biotechnology industry experience, inclusive of R&D, Manufacturing and Fill Finish asset types. He has conducted over 275 assignments in North America and globally, including Asia, Europe, and Mexico. Hess is scheduled to speak Wednesday, October 7 at 10:00 a.m. CST with a focus on bioscience economic development.



    Dr. Regina Benjamin: A leader in preventative medicine, fighting health disparities, and developing innovative community-based health strategies and systems for low-income and rural communities, Regina Benjamin, MD, MBA, is best known for her service as U.S. Surgeon General from 2009-2013. Dr. Benjamin’s notable career has spanned leadership roles in government, higher education, research, and healthcare and honors ranging from being the first African American woman on the board of the American Medical Association to the Nelson Mandela Award for Health and Human Rights. Dr. Benjamin is scheduled to speak Thursday, October 8 at 12:45 p.m. CST delivering the closing keynote address. 

    Additional speakers, organizations, as well as sponsors, will be announced during the next several weeks. Up-to-date information on the agenda and thought leaders presenting can be found on the conference website. Event registration will open soon. 

  • 19 Aug 2020 6:00 AM | Deleted user

    Two Alabama-based organizations are partnering to find cures for common diseases that cause blindness for millions of people worldwide

    In an effort to help medical researchers develop new treatments and cures for blinding eye diseases, Advancing Sight Network and Kailos Genetics created the OcularGeneScreen, a new genetic screening panel, to be used with eye tissue from post-mortem eye donors. The screening will help determine which genes are associated with eye diseases like agerelated macular degeneration (AMD), glaucoma, and Fuch’s Dystrophy.

    “These diseases cause a huge decline in quality of life for so many people,” says Dr. Gregory Grossman, Advancing Sight Network’s Chief Scientific Officer. “By identifying the genes involved, we’re taking a huge step forward in being able to find cures.”

    Advancing Sight Network is a nonprofit organization that has served Alabama for more than 50 years. In addition to providing eye tissue for corneal transplants, the organization invests in medical research in hopes of restoring eyesight to individuals impacted by eye disease.

    “Our goal is to restore eyesight,” says Dr. Grossman. “For the grandparent who can no longer see their grandchild’s face or the person who’s lost their independence due to incurable vision loss, the development of a cure brings hope for a bright future.”

    Kailos Genetics, a biotechnology company based in Huntsville, provides innovative genetic screenings that help people determine their risk for certain diseases like cancer. IndustryWired recently named Kailos Genetics one of the top 8 precision medicine companies in the USA.

    “Our mission is to enable clinical research teams to make advances that impact the health of individuals.” says Troy Moore, Chief Scientific Officer for Kailos Genetics.“Kailos’ TargetRich™ assay development platform combines flexible design and rapid development with the unparalleled insights gained from deep sequencing.”

    The research is funded by a generous grant from the Huntsville-based Alpha Foundation, whose goal is to improve the human condition through grants to educational, scientific and charitable organizations.

    The bottom line, says Dr. Grossman, is finding cures and making them available as quickly as possible. “We want to help people see again. We want the person who is diagnosed with AMD to have hope. We don’t want anyone to lose their livelihood or their independence because of vision loss. Ultimately, that’s what this project is about.”

    Not only will the project potentially help over 150,000 people in Alabama who are affected by irreversible vision loss, these two Alabama organizations could be part of bringing cures to more than 200 million people worldwide affected by these diseases. 

  • 20 Jul 2020 12:59 PM | Deleted user

    Rosser to Support the Alabama Bioscience Community

    BIO Alabama welcomes Master of Biotechnology student  into it’s summer/fall internship program, a program for college students who are intrinsically curious about Alabama’s bioscience industry and are motivated to promote the intellectual and innovative capital that make our state a premier place to invest, start, and grow in bioscience. 

    Austin Rosser, a Master of Biotechnology student from the University of Alabama at Birmingham, was recently accepted to BIO Alabama’s summer/fall internship program. 

    “Finishing my Master of Biotechnology degree during a global pandemic amplified the importance of my degree and my chosen field,” said Austin Rosser. “I’m fortunate to be transitioning into the paid workforce, but volunteer work is equally important to me. BIO Alabama provides an incredible opportunity to expand my skill set, build my network, and contribute to our expanding bioscience community in a meaningful way.”  

    Rosser will spend the rest of his summer and early fall conducting research on tactics, techniques, and strategies that will help BIO Alabama develop an economic development roadmap focused on business attraction and retention, workforce development, and startup and tech transfer within the bioscience community. He will assist in collecting, compiling, and translating data into a consumable report. The final report will be presented at BIO Alabama’s annual conference in October. 

    “It’s an incredible time to be involved in Alabama’s bioscience community and we’re thrilled that Austin chose to volunteer with us even though classes were coming to an end,” said Sonia Robinson, Executive Director of BIO Alabama. “BIO Alabama has a number of initiatives underway including the development of our strategic economic development roadmap and virtual annual conference. Having Austin’s energy and enthusiasm will help us deliver a robust plan as well as curate an annual conference designed to surprise and delight our attendees,” Robinson adds.

    BIO Alabama provides remote internship opportunities throughout the year and is now accepting cover letters and resumes for fall internship and annual conference ambassador opportunities. Interested students may email their cover letter and resume to sonia@bioalabama.com.  In addition to BIO Alabama, a number of bioscience companies across the state welcome interns. Interested students may contact BIO Alabama for more information. Bioscience companies who have available internships are encouraged to send internship opportunities to BIO Alabama for assistance in promoting those opportunities to partner colleges and universities.  

    Interns support the executive director in further connecting our bioscience ecosystem. Internships with BIO Alabama are for college credit and follow the college or university's internship guidelines including minimum hour requirements and deliverables. 


  • 7 Jul 2020 8:23 PM | Deleted user
    • Avanti combining with Croda to expand life sciences products, pharmaceutical services and cGMP production capabilities for biotechnology, pharmaceutical and life science research customers globally
    • Avanti will continue to operate under the Avanti brand and be led by the current management team

    Alabaster, AlabamaAvanti Polar Lipids, Inc. (“Avanti” or the “Company”) today announces it has agreed to be acquired by Croda International, Plc (“Croda”). The combination of two life science leaders brings together Avanti’s expertise in lipid-based drug delivery solutions through its research products and pharmaceutical services and Croda’s range of life science products and cGMP manufacturing capabilities to expand their respective breadth of products and services for biotechnology businesses, academic institutions and pharmaceutical companies globally.

    Avanti was founded in 1967 by Dr. Walter and Rowena Shaw and is a leader in the development and manufacturing of high-purity lipids that are increasingly utilized as drug delivery solutions for complex therapeutic drugs and next generation mRNA vaccines. The Company operates from its campus in Alabama with its skilled workforce of approximately 150 employees, including over 100 scientists. Throughout Avanti’s history it has been an innovator in lipid based products and applications for the life sciences markets and currently serves thousands of leading biopharmaceutical companies and researchers around the world.

    The Company has two primary revenue streams in research products and pharmaceutical services. Since the Company’s founding it has been a leader in developing lipids for life science research and currently offers over 2,000 lipid and adjuvant products serving over 3000 customers globally. The Company also offers pharmaceutical services where it leverages its lipid based expertise to develop and supply drug delivery solutions for complex therapeutics. Avanti provides a comprehensive range of services from formulation and analytical services through cGMP manufacturing of synthetic lipids and adjuvants for clinical and commercial applications.

    Avanti’s know-how and technologies are highly complementary to Croda’s capabilities in drug delivery systems, vaccine adjuvants and immunotherapy. Avanti will be able to combine its leading position in pharmaceutical lipid-based applications with Croda’s access to global markets, greater manufacturing capacity and a broader set of capabilities to expand the range of products and services for the combined customer base.

    Avanti will continue to operate under the Avanti brand and be led by the current management team. It will be part of Croda’s Life Sciences sector and sit within its Health Care business.

    Dr. Walter Shaw, CEO of Avanti, commented: “We are delighted to join Croda, which shares a common vision of innovation to deliver products and services to solve pressing healthcare needs around the world. Avanti has been my life’s work, I am extremely proud of what the Avanti family has accomplished to date and I could not think of a better partner to continue to support our customers and talented employees in their pursuit of solving complex drug delivery challenges in the future.”

    Steve Foots, CEO of Croda, commented: “We have long admired the Avanti team for their deep scientific know-how and are already working together on high-potential commercial opportunities. With their exciting drug delivery technologies, Avanti is a market leader in a high growth niche of the health care market, serving over 3,000 customers globally. Bringing Avanti’s best-in-class expertise into Croda also significantly enhances our presence across the pharma product lifecycle, including early stage R&D, clinical trials, analysis and formulation. I am confident that Avanti will prove transformative to the capabilities and performance of our Life Sciences sector.”

    BlackArch Partners served as exclusive financial advisor to Avanti. Maynard Cooper & Gale served as legal advisor to Avanti.

    Further information:

    Dr. Kacee Sims - Kacee.Sims@avantilipids.com

    About Avanti Polar Lipids, Inc.:

    More at: www.avantilipids.com

    Avanti specializes in the development and production of high-purity polar lipids that are increasingly being used in next-generation drug delivery technology and vaccines. It has two primary revenue streams:

    • Research Products: sales of a wide range of high-purity lipid products for pharmaceutical research and development
    • Pharmaceutical Services: comprehensive liposomal drug delivery development and production solutions. In addition to its formulation and analytical capabilities, Avanti provides a production capability, to the highest quality and regulatory standards (known as Good Manufacturing Practice or GMP), to support customers’ drug development, clinical trials and commercial supply of novel drug delivery systems.

    With its extensive portfolio, Avanti serves biotechnology and large pharmaceutical companies around the world.

    About Croda:

    More at www.croda.com

    Established in 1925, Croda is the name behind sustainable, high performance ingredients and technologies in some of the world’s most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere.

    Croda is a FTSE100 company with over 4,500 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart Science to Improve Lives™. As part of this Purpose, and with around two thirds of its organic raw materials already from bio-based sources, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030.



  • 2 Jul 2020 3:40 PM | Anonymous member

    Interested in turning your innovative ideas into reality?

    On behalf of the U.S. Department of Agriculture, Dawnbreaker will be hosting a workshop to introduce the exciting opportunities offered by the USDA Small Business Innovation Research (SBIR) program. These competitive, grants provide the opportunity to conduct research and explore the development of new technologies, services, and products. The USDA SBIR program offers competitively awarded grants up to $100,000 to qualified small businesses to support the growth of research and ideas into products and services that could lead to significant public benefit in agriculture and community development. Whether you’re an established business, aspiring innovator, or even if you’ve applied for SBIR grant funding in the past, this workshop can help you get set-up for success. Come, learn, grow, and gain a better understanding of the program, the chance to meet with experts and secure a personal proposal consultant, on-site access to laptops to set-up all required registration information, including a DUNS number.

    Proposals will be accepted from the following topic areas:

    » Forests and Related Resources

    » Plant Production and Protection - Biology

    » Animal Production and Protection

    » Air, Water and Soils

    » Food Science and Nutrition

    » Rural Development

    » Aquaculture

    » Biofuels and Biobased Products

    » Small and Mid-Size Farms

    » Plant Production and Protection - Engineering

  • 30 Jun 2020 8:55 AM | Anonymous member

    June 30, 2020 (Huntsville, Ala.) – Everbloom Health, Inc., a Sulfilatec company, has launched a new program called “Burl Gives Back” to address food insecurity. Through this program, the company is donating one bag of its Burl Barley Granola® product for every four bags of granola sold at burlgranola.com. The program was launched during the midst of COVID-19 stay-at-home restrictions and has been successful.

    “Our product donations through the Burl Gives Back program have been much higher than we anticipated,” said Dr. Chris Cummings, CEO of Everbloom Health. “We deeply appreciate the support of our customers and love the opportunity to meet some of the needs of those facing food insecurity.”

    Dr. Cummings explained that “hunger is all too common in our society due to food deserts, economic uncertainty, and other factors. It impacts all ages, from innocent kids to our cherished elderly and even entire families. Additionally, it impacts many within the kidney disease community, where we have a major part of our operations. The Burl Gives Back program is our way of doing what we can to help.”

    Founded in 2018, Everbloom Health offers Burl Barley Granola as a healthy food option made with rolled barley rather than oats. Whole grain barley is used relatively infrequently in the US food supply, yet has many nutritional properties and is also a preferred grain for many renal diets. The company offers its granola as a kidney-friendly food to health-conscious markets.

    Everbloom Health is a subsidiary of Sulfilatec, Inc., a biotech company working to develop new products that address the elevated mortality and morbidity burdens in dialysis populations. Everbloom Health and Sulfilatec are both located at HudsonAlpha Institute for Biotechnology in Huntsville, AL.

    To learn more about the Burl Gives Back program, visit burlgranola.com.

    ###

  • 25 Jun 2020 4:55 PM | Anonymous member

    by Life Science Newswire | Jun 24, 2020 | BiotechnologyCorporate, Finance & Investor | 0 comments

    Caption: The flagship building for the HudsonAlpha Institute for Biotechnology and its associate companies, located at 601 Genome Way, Huntsville AL. Collaborative work between Foresight Biosciences and Van Heron Labs will take place in Suite 4104 at this site.

    Houston, Texas, and Huntsville, Alabama have served as epicenters of innovation for decades, partnering to push boundaries, upend limitations, and put mankind on the moon. In a strategic new alignment, Van Heron Labs, a startup formed in Houston, will begin working alongside Huntsville’s Foresight Biosciences to continue the tradition.

    Both company’s current founders, leadership, and support teams are dominated by Texas and Alabama natives with many current and former students of state institutions (Auburn, U.A.H., U.A.B., U.H., Rice, U.T., U.T. Health, W.T.A.M.U., T.A.M.U.). Van Heron Labs is also named in honor of the late James Van Heron, a widely admired Alabama native holding several microbiology degrees from Auburn University. Together, the two southern companies will take aim at surpassing the boundaries in a burgeoning field: biotechnology.

    Foresight Biosciences are leaders in glycoscience and enzymatic assay development. Their innovative technologies advance glycobiology research and improve the production of glycoprotein therapeutics. The current production of biologics is not only complex and costly, but also plagued with common issues, e.g. high immunogenicity, poor shelf-life, which hinder protein-based drug development. Foresight’s proprietary platform revolutionizes therapeutic protein production to yield higher quality biologics by inducing protein modifications necessary to create more effective human biopharmaceutical therapies. Foresight, aptly named, has also positioned themselves to continue applying their dynamic platform and broad interests to advance our understanding in fields ranging from the metabolic basis of human disease, to microbial ecology and evolution, to human stem cell research, and even agriculture; complemented by the on-going work of Van Heron Labs.

    Van Heron’s mission is to reframe our understanding of organismal and cellular performance. They have created a novel pipeline that uses genetic analysis to design a customized procedure for optimizing metabolism for a particular organism or cell, maximizing growth and product output. A completely bootstrapped company, Van Heron Labs is primed to explode on the biotechnology scene due to the versatility of its technology. Their platform has the potential for astounding flexibility, ranging from increasing the production of valuable cellular products, to directly selecting for organisms in complex nutritional environments, to even other more niche applications spanning nearly every industrial, medical, and research sector. Van Heron Labs has yet to decide what they will disrupt first. However, they feel confident that the mentorship and opportunities that will come from pairing with an experienced company such as Foresight will prove to be a priceless advantage.

    The strength of this partnership’s lies not only in the two companies’ shared multi-disciplinary vision for the future, but also in the complementarity of their two technological platforms. Foresight, like many companies who utilize cellular products, relies on the fidelity of the culture media they use. While industry standards for culture media have largely stagnated of late, Van Heron Labs aims to enhance standard media with their customized formulas that robustly increase a cell’s capabilities and therefore the quality of high-value cellular products. This provides the perfect opportunity for Van Heron Labs to add substantial value for Foresight, while simultaneously demonstrating viability at industry scale. The partnership offers mutual benefits for both companies and the field of biologic production as a whole.

    As of now, prospective collaborative projects will be dynamic and will aim to impact and ameliorate fields like drug and enzyme discovery, development and production as well as industrial fermentation, bioremediation, cell culture, and beyond. Both companies are currently using their platforms to develop technology to help battle COVID-19. In anticipation of continuing collaborative work with Foresight, Van Heron Labs plans to move a significant portion of their laboratory operations from the Texas Medical Center in Houston to the HudsonAlpha Institute for Biotechnology located in Huntsville, Alabama this month. However, VHL also plans to maintain a strong presence and activism within the Houston entrepreneurial ecosystem, which the company cites as the catalyst for the birth and growth of the company. Van Heron Labs hopes that this will be the first of many collaborations between Huntsville and Houston the two cities spearhead the growing life-science entrepreneurship movement in the southern U.S.

    For more information please visit http://foresight-bio.com/ and http://vanheronlabs.com/.

    To read more about HudsonAlpha’s mission and vision, as well as the innovative work being done on the campus, please visit https://hudsonalpha.org/.

    About Foresight Biosciences: Foresight Biosciences provides technology for glycobiology research with an emphasis on creating tools and in vitro technologies to advance protein-based drug development. We are focused on providing benchtop assays for glycoprotein fingerprint analysis, enzymes and convenient kits for identifying, repairing, and modifying protein glycosylation. In addition to our current product portfolio, we are working to develop recombinant expression systems that yield products with human-like surface glycosylations. The end goal is to improve treatments and ultimately prevent human diseases.

    About Van Heron Labs: VHL is a platform technology service that uses a proprietary pipeline to determine the nutrient substrates needed for optimal biosynthesis and growth across organisms and cell types. The one-of-a-kind technology can be deployed for virtually any application which involves or harnesses living cells or bio-matter. VHL is currently focused on addressing speed and scale challenges, particularly for the production of key bio-products. VHL’s platform can be leveraged as a competitive advantage for microbial or cell culture, the production of biologic drugs, enzymes, and other high-value natural or recombinant  products.



  • 24 Jun 2020 8:23 AM | Anonymous member

    June 24, 2020 (Huntsville, Ala.) – The Muscogee (Creek) Nation (MCN), the HudsonAlpha Institute for Biotechnology and HudsonAlpha Health Alliance, have begun a collaboration to bring health and education programs with a focus on genetics and genomics to the tribe. The integration of genomic information in precision medicine is rapidly advancing health care, as an individual’s genome carries important information about disease risks, potential responses to therapy, and appropriate medications. By building programs that integrate genomics into the Muscogee (Creek) Nation Department of Health (MCNDH), its citizens and patients will gain access to these advances. 

    In keeping with tribal leadership’s commitment to improving access to quality and advanced education programs, the collaboration will also provide MCN students and educators access to the latest in genomic science educational tools and classroom support, as well as opportunities to explore careers in biotechnology and genomic medicine through a variety of workforce programs.

    The MCN genomic health program, through a collaboration with the Health Alliance, will involve the implementation of comprehensive clinical genetic testing to citizens receiving care at MCNDH. This will include clinical decision support for MCNDH physicians, access to the Health Alliance’s Genome Gateway portal for electronic delivery of genetic test results, and test-specific education for patients and physicians. The program will be managed with strict adherence to the tribe’s privacy standards, quality protocols and supervision for the purpose of improving health outcomes for MCN citizens.  

    “This exciting program creates a critical bridge between the Muscogee (Creek) Nation and the advanced genomic science and education programs at the HudsonAlpha Institute. We think this program will serve as a new collaborative model that will give MCN a leadership position in Native American health initiatives, empowering their citizens to participate in the biotechnology revolution, while maintaining tribal autonomy,” said Devin Absher, PhD, Director of Genomic Health at HudsonAlpha.  

    “The Muscogee (Creek) Nation Department of Health takes pride in its history of innovation, from being the first tribe in the country to own and operate community hospitals to collaborating with an internationally recognized research institution to improve healthcare delivery for our citizens. This partnership with HudsonAlpha provides a real-world solution to address the significant health disparities our citizens face and will enable us to improve health outcomes for generations to come,” said Shawn Terry, Secretary of Health for the Muscogee Creek Nation.

    ###

    About Muscogee (Creek) Nation: The Muscogee (Creek) Nation is the fourth-largest federally recognized tribe in the United States, headquartered in Okmulgee, Oklahoma. MCN has more than 89,000 citizens.

    About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlpha’s vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 40 diverse biotech companies on campus. To learn more about HudsonAlpha, visit hudsonalpha.org.

Connecting the Bioscience Ecosystem in Alabama

BIO Alabama
Post Office Box 13906
Birmingham, AL 35202

administrator@bioalabama.com

© BIO Alabama

Powered by Wild Apricot Membership Software